At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 166 enrolled
Drug / intervention
RO7239361 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
In Brief
A Phase 3 clinical trial evaluating RO7239361 and Placebo for RO7239361 for Duchenne Muscular Dystrophy. Completed, enrolled 166 participants across 44 sites in 13 countries.
Detailed Summary
This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuchenne Muscular Dystrophy
CountriesArgentina, Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartJul 2017
Primary CompletionApr 2020
TodayJul 2026
First PostedFeb 1, 2017
Enrollment StartJul 6, 2017
Primary CompletionApr 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.4 years ago
Interventions
RO7239361drug
Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Placebo for RO7239361drug
Take placebo subcutaneously on specified days over a 48 week blinded period